Disease · MONDO_0016532
Lennox-Gastaut syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Lennox-Gastaut syndrome. Diseases, record MONDO_0016532. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016532
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 5 of its 12 drugs, from DailyMed, EMA Human Drugs, FDA and PMDA
- Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CANNABIDIOL | CHEMBL190461 | Small molecule | Approval | EMA Human Drugs and FDA | 15 | 13 | 13 | Drugs and targets |
| RUFINAMIDE | CHEMBL1201754 | Small molecule | Approval | DailyMed and PMDA | 7 | 4 | 4 | Drugs and targets |
| CLOBAZAM | CHEMBL70418 | Small molecule | Approval | DailyMed | 6 | 3 | 3 | Drugs and targets |
| TOPIRAMATE | CHEMBL220492 | Small molecule | Approval | DailyMed | 4 | 2 | 2 | Drugs and targets |
| LAMOTRIGINE | CHEMBL741 | Small molecule | Approval | DailyMed and PMDA | 2 | 0 | 0 | Drugs and targets |
| SOTICLESTAT | CHEMBL4298172 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| FENFLURAMINE | CHEMBL87493 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CARISBAMATE | CHEMBL2087003 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| EZOGABINE | CHEMBL41355 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DRONABINOL | CHEMBL465 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets47
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SCN10A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6332 | Drugs and targets |
| SCN8A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6334 | Drugs and targets |
| SCN9A | Sodium channel alpha subunit | 3 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6335 | Drugs and targets |
1 to 10 of 47
See all 47 targetsTrials37
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02224573 | An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes | Phase 3 | 681 | 2022-02-03 | Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
| NCT03936777 | A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome | Phase 3 | 412 | 2025-11-17 | Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy | FENFLURAMINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03355209 | A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome | Phase 3 | 296 | 2025-07-03 | Lennox Gastaut Syndrome | FENFLURAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT04938427 | A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome | Phase 3 | 270 | 2024-08-21 | Lennox Gastaut Syndrome (LGS) | SOTICLESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01160770 | Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome | Phase 3 | 267 | 2013-05-06 | Lennox-Gastaut Syndrome | CLOBAZAM | Its record names the disease | ClinicalTrials.gov |
| NCT00518713 | Clobazam in Patients With Lennox-Gastaut Syndrome | Phase 3 | 238 | 2012-02-09 | Epilepsy, Epilepsy, Generalized, Seizures | CLOBAZAM | Its record names the disease | ClinicalTrials.gov |
| NCT02224560 | Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults | Phase 3 | 225 | 2018-07-27 | Epilepsy, Lennox Gastaut Syndrome | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
| NCT02224690 | A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults | Phase 3 | 171 | 2018-07-27 | Epilepsy, Lennox-Gastaut Syndrome | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
| NCT03635073 | A Study of Soticlestat in Adults and Children With Rare Epilepsies | Phase 2 | 156 | 2026-03-19 | Epilepsy, Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | SOTICLESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT03650452 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies | Phase 2 | 141 | 2021-02-18 | Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome | SOTICLESTAT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 37
See all 37 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dravet Syndrome vs Lennox-Gastaut Syndrome: deaths from any cause | 6 of 315 | 12 of 366 | 681 | NCT02224573 | Trial comparisons |
| Dravet Syndrome vs Lennox-Gastaut Syndrome: serious adverse events | 133 of 315 | 157 of 366 | 681 | NCT02224573 | Trial comparisons |
| Soticlestat vs Placebo: deaths from any cause | 0 of 134 | 0 of 136 | 270 | NCT04938427 | Trial comparisons |
| Soticlestat vs Placebo: serious adverse events | 11 of 134 | 10 of 136 | 270 | NCT04938427 | Trial comparisons |
| GWP42003-P 20 mg/kg/Day Dose vs Placebo: Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period | 38 of 86 | 20 of 85 | 171 | NCT02224690 | Trial comparisons |
| GWP42003-P 20 mg/kg/Day Dose vs Placebo: serious adverse events | 20 of 86 | 4 of 85 | 171 | NCT02224690 | Trial comparisons |
| TAK-935 vs Placebo: deaths from any cause | 0 of 71 | 0 of 70 | 141 | NCT03650452 | Trial comparisons |
| TAK-935 vs Placebo: serious adverse events | 11 of 71 | 13 of 70 | 141 | NCT03650452 | Trial comparisons |
| Clobazam Low Dose vs Clobazam High Dose: serious adverse events | 1 of 32 | 3 of 36 | 68 | NCT00162981 | Trial comparisons |
| Rufinamide (E2080) vs Placebo: serious adverse events | 1 of 29 | 1 of 30 | 59 | NCT01146951 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials20
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016532
GET https://conductscience.org/api/diseases/v1/MONDO_0016532/targets?page=2